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Minocycline improves the 
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therapy: a Hypothesis
Ajit Venniyoor* and Bassim Al Bahrani
National Oncology Center, The Royal Hospital, Muscat, Oman
Skin rash is a side effect of drugs that inhibit epithelial growth factor receptor (EGFR) 
as a part of targeted therapy of cancer. Its appearance and severity correlates with 
survival. Minocycline, an oral tetracycline antibiotic, is recommended as treatment (and 
increasingly, for prevention) of the rash, though infection is seen in only one-third of 
the patients. Minocycline has additional anticancer properties such as poly(ADP-ribose) 
polymerase inhibition. It is proposed that such properties contribute to the efficacy of 
EGFR inhibitors and can also explain the positive correlation between grade of rash and 
survival as patients with higher grades of rash are more likely to receive minocycline. 
Early concurrent administration of minocycline is recommended in patients planned for 
EGFR therapy while awaiting trials proving this hypothesis.
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Inhibition of epithelial growth factor receptor (EGFR) with either monoclonal antibodies (cetuxi-
mab, panitumumab) or tyrosine kinase inhibitors (erlotinib, gefitinib) is approved for the treatment 
of some subsets of cancers of colon, lung, pancreas, and head and neck. One of the major side effects 
of these drugs is an acne-form skin rash (1). Multiple trials have shown that the appearance and the 
degree of rash are associated with improved survival (2, 3). It is recommended that higher degrees 
of rash be treated with tetracyclines, such as minocycline (1), despite studies suggesting that only 
about 40% of them have an infection (4).
Minocycline, in addition to being an antibiotic, has multiple other actions (5). It is a poly(ADP-
ribose) polymerase-1 (PARP-1) inhibitor (6), and there is evidence that inhibition of PARP 
pathway could be useful in EGFR-dependent tumors. EGFR mutants have lower levels of BRCA1 
expression (7) and have deficiencies in the homologous recombination repair pathways that make 
them sensitive to another PARP inhibitor, such as olaparib (8). In triple-negative breast cancer cell 
lines, a combination of EGFR and PARP inhibition have been shown to increase synthetic lethality 
(9). Synergy of EGFR and PARP inhibition has been reported on cell lines (10, 11), and data on 
combination of PARP inhibitors with anti-EGFR monoclonal antibodies has been reviewed (12). 
A trial is currently recruiting head and neck cancer patients in a Phase I trial for the combination 
of cetuximab and olaparib (NCT01758731) (13).
Interestingly, minocycline was chosen for the treatment of skin rash in the first randomized trial 
(conducted by Memorial Sloan Kettering Cancer Centre) for its anti-inflammatory rather than anti-
infective effects (14).
Minocycline also appears to enhance the antitumor effects of 5-FU in tumor CT-26 xenograft 
mice (15). Therefore, it is possible that the increased activity of EGFR inhibitors and correlation with 
degree of skin rash can be attributed partly to concurrent use of minocycline.
Interestingly, the recently published Pan Canadian Rash trial (16) on the use of minocycline 
in the management of skin rash caused by erlotinib in lung cancer showed a trend toward 
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improved survival associated with the early use of minocycline 
(7.6 and 8  months in prophylactic and reactive use) versus 
if used only when severe rash appears (6 months). Thus, this 
hypothesis is worth exploring in prospective randomized 
trials. Analysis of existing data generated in Phase III trials 
using EGFR inhibitors with specific focus on survival versus 
minocycline use could also provide evidence supporting this 
hypothesis.
In the meantime, the use of minocycline should be recom-
mended in patients on EGFR inhibitors even before the appear-
ance of skin rash [in line with current recommendations (17)], for 
a possible survival effect. The antibiotic has been used over pro-
longed periods (3–4 months) for the treatment of acne vulgaris, 
with hyperpigmentation and a lupus-like syndrome as side effects 
(18). Repurposing of (benign) drugs for their anticancer effects 
is an active field of research, and minocycline appears to be an 
active drug for inclusion in this list (19).
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